Skip to McMaster NavigationSkip to Site NavigationSkip to main content
The Forge Logo

Built by McMaster University

The Forge


VoxNeuro Announces Collaboration with the Canadian Armed Forces and Launch of Clinical Study Measuring Impact of Training-Related Sub-Concussive Exposure

The Forge client VoxNeuro Inc., a commercial stage Software-as-a-Medical-Device (SaMD) brain health company that analyzes brain biomarkers to assess cognitive function, has announced a new partnership with the Canadian Armed Forces (“CAF”).

September 27, 2022

VoxNeuro and CAF have partnered to study the cognitive effects following intense military training regimens designed to reflect a combat environment and blast exposure. Despite the high prevalence of cognitive issues in veterans and active military personnel, there is relatively little understanding regarding these cognitive effects and reliable monitoring.

The study will assess the effects of repetitive, sub-concussive exposure (RSCE) on cognitive functioning and brain electrophysiology with CAF personnel undergoing cognitive testing in tandem with EEG recordings before and after military training. The study seeks to understand the relationship between RSCE and behavioural symptoms, vestibular dysfunction, neurophysiology, and cognition to aid in early detection, prevention, treatment and prognosis.

The study will be led by Dr. Kyle Ruiter, PhD, VoxNeuro’s Vice President of Clinical & Scientific Affairs with support from Dr. John Connolly, PhD, VoxNeuro’s Chief Science Officer. “We are very excited for the opportunity to conduct research with the Canadian Armed Forces that will help further our understanding of the cognitive performance of elite military personnel during high intensity, combat-like situations,” said Dr. Ruiter. “This research will hopefully be an important step forward in improving brain health and increasing the safety of the Canadian Armed Forces and other military personnel.”

VoxNeuro and CAF intend for this study to lay the foundation for future collaborative research for years to come. The goal is to understand how to best improve the diagnosis of brain injuries in active military personnel that are exposed to RSCE and to use this information to refine VoxNeuro’s existing in-market testing platform. The Company intends to use this work to support new regulatory filings with Health Canada and the FDA.